Earnings Call Summary | Beyond Air(XAIR.US) Q4 2024 Earnings Conference
Earnings Call Summary | Beyond Air(XAIR.US) Q4 2024 Earnings Conference
The following is a summary of the Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript:
以下是Beyond Air公司（XAIR）2024年第四季度业绩会简介：
Financial Performance:
金融业绩：
FY 2024 revenue reported at $1.2 million, up from zero in the previous year.
Net loss improved slightly to $64.3 million; cash reserves stood at $34.5 million.
2024年营业收入报告为120万美元，比上一年增长了零。
净亏损略有改善，为6430万美元；现金储备为3450万美元。
Business Progress:
业务进展：
LungFit PH launched and used in over 50 US hospitals, treating 1,100 patients.
All hospitals renewed LungFit PH contracts with an increase in multi-year agreements.
LungFit PH在超过50家美国医院中启用，治疗了1100名患者。
所有医院都续签了LungFit PH合同，并增加了多年协议。
Opportunity:
机会：
Potential market expansion with pending FDA approval for LungFit PH in cardiac surgeries.
Strategic partnerships in Asia-Pacific and plans for European market entry.
有望扩大市场，并在心脏手术方面获得FDA批准，本年度日历年底前实现。
在亚太地区建立战略合作伙伴关系，并计划进入欧洲市场。
Risk:
风险：
Delayed milestones could lower FY 2025 revenue expectations.
High dependency on LungFit PH market acceptance and updated system deployments.
延迟的里程碑可能会降低2025财年营收预期。
高度依赖LungFit PH市场接受度和更新系统的部署。
Financial Performance:
金融业绩：
Beyond Air reported FY 2024 revenue of $1.2 million, a significant increase from zero revenue in the previous fiscal year.
Gross margin reported a loss of $1.3 million due to costs related to device upgrades and depreciation of prebuilt devices.
Net loss for the fiscal year 2024 was $64.3 million, slightly improved from the previous year.
Cash, cash equivalents, and marketable securities totaled $34.5 million as of March 31, 2024.
Beyond Air报告，2024财年营收为120万美元，较上一财年无收入显着增长。
由于设备升级成本和预建设设备折旧费用，毛利率报告亏损130万美元。
2024财年净亏损为6430万美元，与上年略有改善。
截至2024年3月31日，现金、现金等价物和可交易证券总计3450万美元。
Business Progress:
业务进展：
Beyond Air successfully launched LungFit PH following FDA approval and completed a crucial software upgrade.
Over 50 hospitals in the U.S. have used LungFit PH to treat more than 1,100 patients totaling over 75,000 therapy hours.
All hospitals using LungFit PH renewed their contracts, with a significant increase in multi-year contracts.
Anticipation of FDA approval for the expansion of LungFit PH label to include cardiac surgery by the end of calendar year 2024.
Beyond Air成功推出LungFit PH，并完成了至关重要的软件升级。
美国超过50家医院使用LungFit PH治疗了1100名患者，治疗时间超过75000小时。
所有使用LungFit PH的医院都续签了合同，并增加了多年协议。
期待FDA在2024年日历年底前批准LungFit PH标签扩展，包括心脏手术。
Opportunities:
机会：
Significant market opportunity with the expansion of LungFit PH label to include cardiac surgeries pending FDA approval.
Establishment of strategic partnerships for the commercialization of LungFit PH in Asia-Pacific regions through Getz Healthcare.
Plans to target European markets pending CE Mark approval.
Introduction of David Webster as Chief Commercial Officer to spearhead market expansion and commercial strategies.
LungFit PH标签扩展至包括心脏手术待FDA批准，市场机会巨大。
通过盖茨医疗在亚太地区建立战略合作伙伴关系，以推广LungFit PH商业化。
计划在CE认证获批后进军欧洲市场。
介绍David Webster作为首席商业官，主导市场扩张和商业策略。
Risks:
风险：
Delays in reaching business and product milestones have adjusted revenue expectations downward for fiscal year 2025.
High dependency on successful market expansion and acceptance of updated LungFit PH systems in new hospitals.
Depreciation costs and suboptimal warehousing impacting gross margins.
未能达到业务和产品里程碑的延误，已将营业收入预期下调至2025财年。
对成功市场拓展和新医院更新LungFit PH系统的接受度高度依赖。
折旧成本和次优的仓储对毛利率产生影响。
More details: Beyond Air IR
更多详情：Beyond Air IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。